Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor Conference
August 28 2024 - 7:00AM
Business Wire
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology
company leveraging a deep understanding of immunobiology to develop
novel therapeutics to treat severe autoimmune and inflammatory
disorders, today announced that it will present and host investor
meetings at the Wells Fargo Healthcare Conference and H.C.
Wainwright’s 26th Annual Global Investor Conference.
Management will provide an overview of the Company’s
multi-cytokine inhibitor programs and platform, currently focused
on dermatological and gastrointestinal indications, as well as the
ongoing development of itolizumab in partnership with Ono
Pharmaceutical and Ono’s pending option exercise decision to
potentially acquire Equillium’s rights to itolizumab. Management
will be available for one-on-one meetings during both
conferences.
Conference:
Wells Fargo Healthcare
Conference
Location:
Encore Boston Harbor
Dates:
Wednesday, September 4 – Friday,
September 6
Presentation:
Thursday, September 5, 1:30 pm
Pacific Time | 4:30 pm Eastern Time
Conference:
H.C. Wainwright, 26th Annual
Global Investor Conference
Location:
Lotte New York Palace Hotel
Dates:
Monday, September 9 – Wednesday,
September 11
Presentation:
Tuesday, September 10, 5:00 am
Pacific Time | 8:00 am Eastern Time
Webcast access for both conferences will be available on the
Events & Presentations page under the Investor Relations tab on
the Company’s website. An archived replay of both presentations
will be available for 90 days.
About Equillium
Equillium is a clinical-stage biotechnology company leveraging a
deep understanding of immunobiology to develop novel therapeutics
to treat severe autoimmune and inflammatory disorders with high
unmet medical need. The company’s pipeline consists of the
following novel first-in-class immunomodulatory assets and product
platform targeting immuno-inflammatory pathways. EQ101: a selective
tri-specific cytokine inhibitor targeting IL-2, IL-9, and IL-15;
recently announced positive results from a Phase 2 proof-of-concept
clinical study of patients with alopecia areata. EQ302: an orally
delivered, selective bi-specific cytokine inhibitor targeting IL-15
and IL-21; currently in pre-clinical development. The
multi-cytokine platform: generates rationally designed composite
peptides that selectively block key cytokines at the shared
receptor level targeting pathogenic cytokine redundancies and
synergies while preserving non-pathogenic signaling. Itolizumab: a
monoclonal antibody that targets the CD6-ALCAM signaling pathway
which plays a central role in the modulation of effector T cells;
currently under evaluation in a Phase 3 clinical study of patients
with acute graft-versus-host disease (aGVHD) and announced positive
data from a Phase 1b clinical study of patients with lupus/lupus
nephritis in April 2024. Equillium acquired rights to itolizumab
through an exclusive partnership with Biocon Limited and has
entered a strategic partnership with Ono Pharmaceutical Co., Ltd.,
for the development and commercialization of itolizumab under an
option and asset purchase agreement.
For more information, visit www.equilliumbio.com.
Forward Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements may be identified by the use of
words such as "anticipate", "believe", “could”, “continue”,
"expect", "estimate", “may”, "plan", "outlook", “future” and
"project" and other similar expressions that predict or indicate
future events or trends or that are not statements of historical
matters. Because such statements are subject to risks and
uncertainties, many of which are outside of Equillium’s control,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Risks that contribute
to the uncertain nature of the forward-looking statements include:
Equillium’s ability to execute its plans and strategies; risks
related to performing clinical studies; and whether the results
from clinical studies will validate and support the safety and
efficacy of Equillium’s product candidates. These and other risks
and uncertainties are described more fully under the caption "Risk
Factors" and elsewhere in Equillium's filings and reports, which
may be accessed for free by visiting the Securities and Exchange
Commission’s website at www.sec.gov and on Equillium’s website
under the heading “Investors.” Investors should take such risks
into account and should not rely on forward-looking statements when
making investment decisions. All forward-looking statements
contained in this press release speak only as of the date on which
they were made. Equillium undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date on which they were made, except as required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240828602410/en/
Investor Contact Michael Moore Vice President, Investor
Relations & Corporate Communications 619-302-4431
ir@equilliumbio.com
Equillium (NASDAQ:EQ)
Historical Stock Chart
From Nov 2024 to Dec 2024
Equillium (NASDAQ:EQ)
Historical Stock Chart
From Dec 2023 to Dec 2024